HBM Holdings Ltd. (2142) AI Stock Analysis

• Market Cap: HK$10.51B
• Dividend Yield: N/A
• Average Volume (3M): 8.63M
• Price to Earnings (P/E): 16.1
• Beta (1Y): 1.23
• Revenue Growth: 59.70%
• EPS Growth: 239.97%
• Country: HK
• Employees: 183
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.70
• Shares Outstanding: 894,168,500
• 10 Day Avg. Volume: 6,681,047
• 30 Day Avg. Volume: 8,634,233
• PEG Ratio: -0.75
• Price to Book (P/B): 1.48
• Price to Sales (P/S): 4.83
• P/FCF Ratio: 6.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$18.00
• Price Target Upside: 49.01% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: HK$11.50 ▼(-4.80% Downside)

The overall stock score of 51 reflects the company's mixed financial performance, characterized by strong gross margins but declining profitability and cash flow issues. Technical analysis indicates a bearish trend with weak momentum, while valuation suggests moderate pricing. The absence of earnings call and corporate events data limits further insights.

Positive Factors

High gross margin

An 88.2% gross margin indicates durable cost control or pricing power in core activities. Sustained high gross margins provide a structural buffer against revenue volatility, enabling reinvestment into properties and financial businesses and supporting long-term profitability.

Improving leverage profile

Lower debt-to-equity and a ~58% equity ratio reduce financial risk and increase strategic flexibility. Improved leverage supports capacity for acquisitions or capex, lowers interest burden long-term, and strengthens resilience across property and asset-management cycles.

Diversified business model

Revenue from rentals, asset-management fees, advisory services and capital gains spreads risk across markets and business cycles. This structural diversification smooths cash flows, reduces single-sector exposure and supports more stable earnings over a multi-quarter horizon.

Negative Factors

Weak operating cash generation

Lack of operating cash flow and zero free cash flow undermines the firm's ability to fund capex, service debt or return capital without external financing or asset sales. Over months this reduces strategic optionality and raises refinancing and liquidity risk.

Declining profitability and margins

A sharp drop in net margin and negative operating margins signal structural earnings pressure from higher costs or weaker core income. Persistent margin erosion constrains retained earnings, hampers reinvestment, and weakens the business's ability to weather downturns.

Inconsistent revenue and shrinking assets

Volatile or declining top-line and a shrinking asset base limit scale benefits in property and asset-management operations. Over time this can reduce rental/fee income potential, complicate portfolio optimization, and impede sustainable long-term growth.

HBM Holdings Ltd. Business Overview & Revenue Model

Company Description

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

How the Company Makes Money

HBM Holdings Ltd. generates revenue through multiple streams, primarily from rental income derived from its property investments, which include office spaces and commercial real estate. Additionally, the company earns revenue through its financial services division, which may involve asset management fees, advisory services, and transaction fees. Strategic partnerships with other financial institutions and real estate developers enhance its investment opportunities, while ongoing asset management allows for the optimization of returns on its investment portfolio. Furthermore, potential capital gains from the appreciation of property values and financial assets contribute significantly to the company's overall earnings.

HBM Holdings Ltd. Financial Statement Overview

Summary

HBM Holdings Ltd. shows a mixed financial performance with strong gross margins but declining profitability and cash flow issues. While the balance sheet remains stable with improving leverage ratios, the lack of revenue growth and operational cash generation could hinder long-term growth prospects.

Income Statement

The company has shown inconsistent revenue growth with a significant drop from 2023 to 2024. Gross profit margin remains strong at 88.2% in 2024, indicating good cost control. However, the net profit margin has declined to 7.3% in 2024, reflecting reduced profitability compared to 25.5% in 2023. The negative EBIT and EBITDA margins in 2024 highlight operational inefficiencies.

Balance Sheet

The balance sheet reflects a stable equity position with an equity ratio of 57.9% in 2024. The debt-to-equity ratio improved to 0.49 from 0.55 in 2023, indicating better leverage management. However, the high level of cash compared to total debt suggests liquidity, yet the declining total assets may pose future challenges to asset management.

Cash Flow

The cash flow statement shows challenges with no positive operating cash flow and zero free cash flow in 2024. This indicates potential issues in generating cash from operations, which could affect financial flexibility. The absence of free cash flow growth further underscores cash flow constraints.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	65.06M	38.10M	89.50M	40.66M	4.31M	14.11M
Gross Profit	59.33M	33.61M	87.47M	40.53M	4.17M	13.66M
EBITDA	32.64M	-2.08M	31.18M	-130.21M	-130.84M	-290.91M
Net Income	37.21M	2.78M	22.80M	-137.27M	-137.88M	-296.54M
Balance Sheet
Total Assets	380.47M	215.01M	228.48M	232.12M	282.36M	388.74M
Cash, Cash Equivalents and Short-Term Investments	320.69M	167.22M	140.72M	171.71M	216.30M	356.95M
Total Debt	64.67M	61.34M	66.01M	90.93M	19.47M	1.73M
Total Liabilities	96.89M	90.96M	108.85M	139.62M	59.45M	27.73M
Stockholders Equity	282.70M	124.45M	119.99M	92.83M	223.19M	361.19M
Cash Flow
Free Cash Flow	-5.75M	30.44M	-21.60M	-118.40M	-139.81M	-35.99M
Operating Cash Flow	-5.70M	30.68M	-19.12M	-99.96M	-125.61M	-35.39M
Investing Cash Flow	1.75M	6.55M	28.09M	137.59M	-76.90M	-93.53M
Financing Cash Flow	-4.32M	-10.24M	-29.14M	70.58M	1.59M	357.86M

HBM Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2142, the sentiment is Negative. The current price of 12.08 is below the 20-day moving average (MA) of 13.05, below the 50-day MA of 13.16, and above the 200-day MA of 11.60, indicating a neutral trend. The MACD of -0.39 indicates Positive momentum. The RSI at 40.29 is Neutral, neither overbought nor oversold. The STOCH value of 26.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2142.

HBM Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2256	57 Neutral	HK$8.50B	44.66	6.73%	―	23.37%	―
9966	53 Neutral	HK$8.68B	33.97	13.34%	―	206.58%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2142	51 Neutral	HK$10.51B	16.10	35.80%	―	59.70%	239.97%
2616	42 Neutral	HK$7.80B	-17.23	-95.84%	―	-55.64%	-158.67%
2157	40 Underperform	HK$8.66B	-41.39	-21.42%	―	240.05%	-140.09%

HBM Holdings Ltd. Corporate Events

HBM Holdings Launches Up to HK$300 Million On‑Market Share Buyback

HBM Holdings Limited has announced a plan to repurchase its own shares on the open market, authorising buybacks of up to HK$300 million under its existing and future shareholder-approved repurchase mandates. The board believes the current share price undervalues the company’s intrinsic value and business prospects, and views the buyback as a signal of confidence in its outlook and a tool to enhance shareholder value, while stressing that any repurchases will be executed in compliance with Hong Kong listing rules and other applicable laws, subject to market conditions, and at the board’s discretion, with no assurance on timing, volume or price.

The most recent analyst rating on (HK:2142) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.

HBM Holdings Deepens Ties With Spruce Biosciences via Warrant Exercise

HBM Holdings Limited has exercised a warrant obtained under its license and collaboration agreement between its incubated biotech unit HBM Alpha Therapeutics and U.S.-based Spruce Biosciences Inc., converting it into an equity stake in the partner company. Following the warrant exercise on 19 January 2026, HBM now holds approximately 3.8% of Spruce’s total outstanding shares and about 3.1% on a fully diluted basis, a move that deepens the strategic alignment between the parties but is small enough that it does not trigger Hong Kong Listing Rules reporting, announcement or shareholder approval requirements, indicating limited immediate financial impact while reinforcing HBM’s long-term collaborative position in hormone-related therapeutics.

The most recent analyst rating on (HK:2142) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.

HBM Holdings Grants 309,000 Share Options to Non-Connected Employee

HBM Holdings Limited has granted 309,000 share options to a non-connected employee under its existing share option scheme, with an exercise price of HK$12.76 per share and a 10-year exercise period. The options will vest in three tranches between December 2027 and December 2029 subject to performance appraisals, and are governed by a clawback mechanism for misconduct or termination; the move is intended to align the employee’s interests with shareholders and incentivise long-term value creation without requiring shareholder approval and while remaining within Hong Kong listing rule limits on option grants.

The most recent analyst rating on (HK:2142) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.

HBM Holdings Partners with Bristol Myers Squibb for Antibody Development

HBM Holdings Ltd. has entered into a global strategic collaboration and license agreement with Bristol Myers Squibb to develop next-generation multi-specific antibodies. This partnership could bring Harbour BioMed up to $1.125 billion in payments and royalties, potentially enhancing its market position and offering significant opportunities for growth.

The most recent analyst rating on (HK:2142) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.

HBM Holdings Enhances Collaboration with AstraZeneca for Biotherapeutic Development

HBM Holdings Ltd. has announced an advancement in its global collaboration with AstraZeneca, aimed at discovering and developing next-generation biotherapeutics. The amendment to their existing agreement enhances the scope of their partnership, maintaining the original economic terms, and underscores their commitment to leveraging combined expertise in biotechnology.

The most recent analyst rating on (HK:2142) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.

HBM Holdings Partners with Pfizer for Antibody Discovery

HBM Holdings Ltd. has announced a non-exclusive license agreement with Pfizer, allowing Pfizer global access to Nona Biosciences’ HCAb platform for preclinical antibody discovery. This collaboration aims to accelerate the development of fully human heavy chain-only antibodies for various disease indications, potentially enhancing HBM’s industry positioning and offering milestone payments that could benefit stakeholders.

The most recent analyst rating on (HK:2142) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.

HBM Holdings Partners with Umoja Biopharma for CAR-T Cell Development

HBM Holdings Ltd. has announced a new evaluation and license agreement with Umoja Biopharma to develop in vivo CAR-T cell products. This collaboration combines HBM’s proprietary platforms with Umoja’s VivoVec™ technology, potentially enhancing the reach and effectiveness of CAR-T therapies. The agreement includes upfront payments and milestone fees for HBM, while Umoja will handle further development and commercialization, potentially strengthening HBM’s position in the biotechnology sector.

The most recent analyst rating on (HK:2142) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.